In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Almirall: Adapting Primary-Care-focused R&D to a Specialist World

Executive Summary

Late-stage COPD candidate aclidinium could transform mid-sized Almirall. This is what’s exciting the dozen or more analysts that cover such long-acting muscarinic antagonists; it’s the potential $2 billion drug that “could double or treble the size of this company in a very short time,” sums up one analyst. At the same time, the newly-listed company's other challenge is to monetize the fruits of its primary-care-focused R&D in a world that's going specialist.

Related Content


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts